Objective : The purpose of this clinical research was to create an assessment for patients with muscle disease who wish to continue driving by investigating their motor function and driving experience. Methods : Twenty-four patients with muscle disease who visited our hospital from December 2009 to April 2010 were enrolled in our research. For patients who were still driving, physiatrists evaluated their motor functions, examined simulated driving motions and recorded their driving capabilities and techniques, their ability to get into and out of the vehicle and their ability to store and remove their wheelchairs. Patients no longer driving were asked why they had given up driving. Results : Fifteen patients who continued driving had enough upper limb strength and could simulate driving motions, though the location and degree of their muscle weakness were variable. Five of fifteen drove with the aid of a hand-operated brake and accelerator. Seven needed personal assistance: three to get into and out of the vehicles, six to store and remove wheelchairs. The nine patients who had stopped driving reported that the primary reason for discontinuing driving was that they recognized their muscles were insufficient to control the vehicle. Conclusions : We propose to evaluate muscle strength and to test simulated driving motions when assessing patients with muscle disease. A hand-operated brake and accelerator is efficient for patients with lower limb muscle weakness. However, since no efficient automobile modifications are available for those patients who cannot get into and get out of their vehicles or store and remove their wheelchairs by themselves, we suggest arranging personal assistance for such patients.

This study evaluated the exercise profile (heart rate, cycling speed and pedal cadence) during 25-30 km cycling and fitness and health level for adults (11 males: 69.6 ± 4.7 yrs; 6 females: 66.3 ± 4.9 yrs) with a recreational cycling habit (27.6 ± 14.8 km/week). Exercise intensity at a constant speed on a flat road during male and female cycling was 71.2 ± 11.5 and 66.8 ± 11.4% heart rate reserved (HRR), respectively. Exercise intensity over 60% HRR occupied 72% of cycling time. Peak intensity during male and female cycling was 89.2 ± 8.9 and 93.1 ± 6.1% HRR, respectively. VO2max and CS (chair stand)-30 test for male and female were 40.3 ± 4.3 and 37.7 ± 2.4 ml/kg/min, and 30.8 ± 3.1 and 30.1 ± 3.2 times, respectively. The muscle cross-sectional area of thigh extensor and flexor measured by MRI were 55.4 ± 6.5 and 58.3 ± 13.3 cm² for male, and 45.5 ± 6.4 and 50.2 ± 5.7 cm² for female, respectively. Blood profile for HDL-C (cholesterol), LDL-C and HbA1c (JDS) for male and female were 65.9 ± 8.2 and 67.9 ± 10.6 mg/dl, 112.3 ± 32.0 and 130.6 ± 12.3 mg/dl, and 4.8 ± 0.4 and 4.7 ± 0.1%, respectively. Fitness level and blood profile results were superior to those of the same aged adults. We concluded that the exercise intensity of cycling by middle and older adults with a recreational cycling habit is high and their fitness and health level are higher than average adults.

We demonstrate an aberrant ramification pattern of the renal and testicular vessels. On both sides, the anterior and posterior renal veins emerged from the renal. On the right side, the anterior renal vein collected the right testicular vein and drained into the inferior vena cava, while the posterior one directly drained into the inferior vena cava. Two retrocaval testicular arteries originated from the aorta. On the left side, the perinephric vein drained from the abdominal wall and adrenal gland and joined the anterior renal vein. The anterior renal vein also collected the testicular, suprarenal, and inferior phrenic veins. The posterior one received the other testicular vein and the first three lumbar veins. These renal veins converged, passed anteriorly to the aorta, and drained into the inferior vena cava. Knowledge of the varied anatomy of these vessels will contribute to safe surgical approach to the kidneys.

We demonstrate an aberrant ramification pattern of the renal and testicular vessels. On both sides, the anterior and posterior renal veins emerged from the renal. On the right side, the anterior renal vein collected the right testicular vein and drained into the inferior vena cava, while the posterior one directly drained into the inferior vena cava. Two retrocaval testicular arteries originated from the aorta. On the left side, the perinephric vein drained from the abdominal wall and adrenal gland and joined the anterior renal vein. The anterior renal vein also collected the testicular, suprarenal, and inferior phrenic veins. The posterior one received the other testicular vein and the first three lumbar veins. These renal veins converged, passed anteriorly to the aorta, and drained into the inferior vena cava. Knowledge of the varied anatomy of these vessels will contribute to safe surgical approach to the kidneys.

We demonstrate an aberrant ramification pattern of the renal and testicular vessels. On both sides, the anterior and posterior renal veins emerged from the renal. On the right side, the anterior renal vein collected the right testicular vein and drained into the inferior vena cava, while the posterior one directly drained into the inferior vena cava. Two retrocaval testicular arteries originated from the aorta. On the left side, the perinephric vein drained from the abdominal wall and adrenal gland and joined the anterior renal vein. The anterior renal vein also collected the testicular, suprarenal, and inferior phrenic veins. The posterior one received the other testicular vein and the first three lumbar veins. These renal veins converged, passed anteriorly to the aorta, and drained into the inferior vena cava. Knowledge of the varied anatomy of these vessels will contribute to safe surgical approach to the kidneys.

We demonstrate an aberrant ramification pattern of the renal and testicular vessels. On both sides, the anterior and posterior renal veins emerged from the renal. On the right side, the anterior renal vein collected the right testicular vein and drained into the inferior vena cava, while the posterior one directly drained into the inferior vena cava. Two retrocaval testicular arteries originated from the aorta. On the left side, the perinephric vein drained from the abdominal wall and adrenal gland and joined the anterior renal vein. The anterior renal vein also collected the testicular, suprarenal, and inferior phrenic veins. The posterior one received the other testicular vein and the first three lumbar veins. These renal veins converged, passed anteriorly to the aorta, and drained into the inferior vena cava. Knowledge of the varied anatomy of these vessels will contribute to safe surgical approach to the kidneys.

We demonstrate an aberrant ramification pattern of the renal and testicular vessels. On both sides, the anterior and posterior renal veins emerged from the renal. On the right side, the anterior renal vein collected the right testicular vein and drained into the inferior vena cava, while the posterior one directly drained into the inferior vena cava. Two retrocaval testicular arteries originated from the aorta. On the left side, the perinephric vein drained from the abdominal wall and adrenal gland and joined the anterior renal vein. The anterior renal vein also collected the testicular, suprarenal, and inferior phrenic veins. The posterior one received the other testicular vein and the first three lumbar veins. These renal veins converged, passed anteriorly to the aorta, and drained into the inferior vena cava. Knowledge of the varied anatomy of these vessels will contribute to safe surgical approach to the kidneys.

A novel coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), caused a worldwide pandemic. Our aim in this study is to produce new fusion inhibitors against SARS-CoV-2, which can be the basis for developing new antiviral drugs. The fusion core comprising the heptad repeat domains (HR1 and HR2) of SARS-CoV-2 spike (S) were used to design the peptides. A total of twelve peptides were generated, comprising a short or truncated 24-mer (peptide #1), a long 36-mer peptide (peptide #2), and ten peptide #2 analogs. In contrast to SARS-CoV, SARS-CoV-2 S-mediated cell-cell fusion cannot be inhibited with a minimal length, 24-mer peptide. Peptide #2 demonstrated potent inhibition of SARS-CoV-2 S-mediated cell-cell fusion at 1 µM concentration. Three peptide #2 analogs showed IC50 values in the low micromolar range (4.7-9.8 µM). Peptide #2 inhibited the SARSCoV-2 pseudovirus assay at IC50=1.49 µM. Given their potent inhibition of viral activity and safety and lack of cytotoxicity, these peptides provide an attractive avenue for the development of new prophylactic and therapeutic agents against SARS-CoV-2.

A novel coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), caused a worldwide pandemic. Our aim in this study is to produce new fusion inhibitors against SARS-CoV-2, which can be the basis for developing new antiviral drugs. The fusion core comprising the heptad repeat domains (HR1 and HR2) of SARS-CoV-2 spike (S) were used to design the peptides. A total of twelve peptides were generated, comprising a short or truncated 24-mer (peptide #1), a long 36-mer peptide (peptide #2), and ten peptide #2 analogs. In contrast to SARS-CoV, SARS-CoV-2 S-mediated cell-cell fusion cannot be inhibited with a minimal length, 24-mer peptide. Peptide #2 demonstrated potent inhibition of SARS-CoV-2 S-mediated cell-cell fusion at 1 µM concentration. Three peptide #2 analogs showed IC50 values in the low micromolar range (4.7-9.8 µM). Peptide #2 inhibited the SARSCoV-2 pseudovirus assay at IC50=1.49 µM. Given their potent inhibition of viral activity and safety and lack of cytotoxicity, these peptides provide an attractive avenue for the development of new prophylactic and therapeutic agents against SARS-CoV-2.